Bayer to Acquire Visible Genetics, Inc.

Combined with Bayer's Versant HIV and hepatitis C virus (HCV) viral nucleic acid tests, these will enable Bayer to have a leading position in the nucleic acid diagnostic (NAD) segment of the professional laboratory market. The acquisition will also include all VGI sequencing assays, such as hepatitis assays, currently in development.

"This acquisition is another milestone in our ongoing strategy to expand our infection disease portfolio that began with our acquisition of Chiron Diagnostics in 1998,” said Rolf Classon, president of Bayer Business Group Diagnostics. "It also supports our strategy to bring to market molecular diagnostic tests that assist the physician in the diagnosis and monitoring of disease and treatment regimens.”





Related Links:
Bayer Diagnostics
Visible Genetics